Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.47 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701726 | 0.89 | LMNA (0.58) | LMNAALDH1A1HTTGPR132KMT2A | |
| SCHEMBL13702401 | 0.86 | LMNA (0.55) | LMNAHTTSLC2A1GPR132POLB | |
| SCHEMBL13702128 | 0.84 | MAOB (0.57) | LMNAHTTSLC2A1GPR132POLB | |
| SCHEMBL13701700 | 0.82 | LMNA (0.54) | LMNAALDH1A1HTTGPR132TSHR | |
| SCHEMBL13701720 | 0.81 | LMNA (0.67) | LMNAALDH1A1TSHRMAPK1KMT2A | |
| SCHEMBL13701712 | 0.80 | LMNA (0.65) | LMNAALDH1A1MAPK1KMT2ASMPD1 | |
| SCHEMBL12133228 | 0.78 | LMNA (0.82) | LMNAALDH1A1HTTPOLBMAPK1 | |
| SCHEMBL13701749 | 0.76 | RAB9A (0.59) | LMNAALDH1A1HTTTSHRMAPK1 | |
| SCHEMBL13701690 | 0.76 | SMPD1 (0.71) | LMNAALDH1A1GPR132KMT2ASMPD1 | |
| SCHEMBL13097043 | 0.75 | LTA4H (0.53) | SLC2A1SLC2A4SLC2A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | LMNA 1843/4885ALDH1A1 376/4885HTT 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.